Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and the US Food and Drug Administration (FDA) have already set wheels in motion for a legal challenge.

In a 7 February statement on X, Hims & Hers stated: “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalised care.”

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Shares in Novo rose 7.3% to DKr 317.05 ($50.36) at market open on 9 February, up from a market close of DKr 295.5 on 6 February. The Danish drugmaker has a market cap of DKr 1.4tn.

Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide, pursuant to a prescription. While they are not FDA-approved, they can be made in certain situations, such as shortages or under personalised regimens. However, there are blurred legislative lines on telehealth companies undertaking mass-compounding.

Despite Hims & Hers conceding, Novo announced it had filed a lawsuit against the telehealth company for infringing on its semaglutide patent on 9 February.

“We’ve taken legal action to protect the American public and our intellectual property and will continue to work with regulators, law enforcement and other key stakeholders to ensure patients have access to FDA-approved safe and effective medicines,” said John Kuckelman, Novo’s group general counsel of global legal, IP and security.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Novo has had to battle erosion in the obesity market amid pressure from drugs developed by Eli Lilly and compounded products being sold by telehealth providers. A main component of Novo’s growth strategy relies on sales for its recently launched Wegovy pill in the US.

In a statement to Pharmaceutical Technology, Hims & Hers said: “Novo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalised care. Once again, big pharma is weaponising the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer.”

Novo’s legal challenge follows a similar move by the US Department of Health and Human Services (HHS) to hold Hims & Hers accountable. HHS general counsel Mike Stuart said the company had potentially breached US law.  

On 6 February, Stuart said: “Based on a review of the applicable facts, earlier today referred Hims & Hers Health, the Department of Justice for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

The legal saga comes as Hims & Hers pressed ahead with airing a commercial at the Super Bowl on 8 February. The 60-second ad, called People Live Longer, draws attention to the widening wealth gap in health outcomes across the US.

The slot was less controversial than one aired by the company at the 2025 Super Bowl, which focused on its weight loss drug offerings by attacking the state of the obesity treatment landscape in the US. The commercial attracted anger from politicians and pharma companies, though it reignited the debate around how much power large drugmakers possess in healthcare frameworks.

Novo Nordisk also broadcast an advert during the Super Bowl for the Wegovy pill featuring celebrities including DJ Khaled and Kenan Thompson.